跳至主要内容
临床试验/CTRI/2023/10/058629
CTRI/2023/10/058629招募中4 期

Open Label, Single Arm Clinical Study to Evaluate the safety and efficacy of Navroop- DS in patients suffering from Oligomenorrhea. - NI

Ambic Ayurved India Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Females from 18 to 45 years of age.
  • 2. Females suffering from Oligomenorrhea.
  • 3. If female with childbearing potential, must be willing to practice an acceptable form of birth control for the duration of the study.
  • 4. Females that are able to give written informed consent in a manner approved by the institutional ethics committee and comply with the requirements of the study.
  • 5. Females willing to avoid participation in any other interventional clinical trial for the duration of the study.

排除标准

  • 1. Females that are pregnant, breast feeding, or planning to get pregnant during the study.
  • 2. Females that have participated in any other interventional clinical trial in the previous 90 days.
  • 3. Females with known sensitivity to any of the constituents of the investigational product.

研究者

发起方
Ambic Ayurved India Pvt. Ltd.

相似试验

Study to Evaluate the safety and efficacy of... | 临床试验